Physician Photo

John T. Mullen, MD

Visiting Surgeon, Department of Surgery

Director, General Surgery Residency Program

  • Phone: 617-726-4241
Surgical Oncology
Department of Surgery


  • Cancer Center
  • Stomach Cancer
  • Sarcoma and Connective Tissue Oncology
  • Gastrointestinal Cancers
  • Digestive Healthcare Center
  • Swallowing and Heartburn Center
Clinical Interests
Soft tissue sarcoma
Stomach (gastric) cancer
Retroperitoneal sarcoma
Gastrointestinal stromal tumor (GIST)
Carcinoid tumor
Desmoid tumor
Gastrointestinal cancer
Boston: Massachusetts General Hospital
Waltham: Mass General West
Medical Education
MD, University of California Davis School of Medicine
Residency, Massachusetts General Hospital
Fellowship, Massachusetts General Hospital
Fellowship, University of Texas - MD Anderson Cancer Center
Board Certifications
Surgery, American Board of Surgery
Patient Age Group
Accepting New Patients
Accepting New Patients


I am active in clinical and translational research in an effort to optimize the treatment and outcomes of patients with soft tissue sarcomas, desmoid tumors, and cancers of the stomach.

Current Translational Research Projects:

Principal Investigator. Comparative Genomics of Retroperitoneal Liposarcoma.

Current Prospective Clinical Trials:

Phase I/II Trial of Pre-Operative Image Guided Intensity Modulated Proton Radiation Therapy (IMPT) with Simultaneously Integrated Boost to the High Risk Margin for Retroperitoneal Sarcomas.

Phase I Trial of Bevacizumab, Metronomic Doxorubicin, and Radiation Therapy for Resectable Soft Tissue Sarcomas.


View my most recent publications at PubMed

Ahmad R, Schmidt BH, Rattner DW, Mullen JT. Factors influencing readmission after curative gastrectomy for gastric cancer. J Am Coll Surg 2014;218:1215-1222.

Schoenfeld JD, et al. The impact of positive margins on outcome among patients with gastric cancer treated with radiation. Am J Clin Oncol 2014;Feb 26 (epub ahead of print).

Look-Hong NJ, Hornicek FJ, Harmon DC, et al.  Neoadjuvant chemoradiotherapy for patients with high-risk extremity and truncal sarcomas: A 10-year single institution retrospective study. Eur J Cancer 2012;49:875-883.

Mullen JT et al.  b-Catenin mutation status and outcomes in sporadic desmoid tumors.  Oncologist 2013;18:1043-1049.

Mullen JT et al.  Prognostic significance of treatment-induced pathologic necrosis in extremity and truncal soft tissue sarcoma after neoadjuvant chemoradiotherapy. Cancer 2014.


Surgical Oncology Associates
55 Fruit Street
Boston, MA 02114-2696

Phone: 617-726-4241
Fax: 617-724-3895

Mass General West
52 Second Avenue
Waltham, MA 02451

Phone: 781-487-6100
Fax: 781-487-6201